Frontotemporal Disorders Treatment Market Size (2024 - 2029)

The frontotemporal disorders treatment market is projected to experience significant growth, driven by the increasing prevalence of dementia and related cognitive impairments, which have been exacerbated by the COVID-19 pandemic. The market's expansion is further supported by enhanced understanding of the disorders' pathogenic mechanisms, leading to potential disease-modifying therapies. Government and non-government funding for drug development is also contributing to market growth, despite challenges such as cost issues and limited awareness in some regions.

Market Size of Frontotemporal Disorders Treatment Industry

Frontotemporal Disorders Treatment Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR 7.20 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Frontotemporal Disorders Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Frontotemporal Disorders Treatment Market Analysis

The frontotemporal disorders treatment market is expected to register a CAGR of 7.2% during the forecast period.

  • The outbreak of the pandemic positively impacted the market. The cases of dementia, anxiety and cognitive impairment significantly increased during COVID-19 among all age groups. For instance, according to a study published by the National Center for Biotechnology Information (NCBI) in June 2020, people with cognitive impairment and dementia, in general, were more likely to have a greater risk for COVID-19 exposure and both caregivers and care receivers were undergoing considerable stress than usual during the pandemic. Such a scenario increased the rate of frontotemporal disorders among people.
  • Furthermore, people who have suffered from COVID-19 have also reported suffering from frontotemporal disorders. For instance, a study published in the journal Frontiers in Aging Neuroscience in October 2020 found that some patients who recovered from COVID-19 had sleeplessness, depression, anxiety, post-traumatic stress disorder, and cognitive impairment. Thus, considering such factors, the market witnessed considerable growth during the pandemic and is expected to continue the same during the forecast period.
  • The growing prevalence of dementia and other frontotemporal disorders is one of the major factors propelling the market growth. For instance, as per the data published by the NCBI in March 2021, an estimated 6.2 million Americans aged 65 and older were known to be living with Alzheimer's dementia in 2020. The report also stated that the number could grow to 13.8 million by 2060, barring the development of medical breakthroughs to prevent, slow, or cure Alzheimer's dementia.
  • Similarly, the World Health Organization (WHO) reported in September 2022 that more than 55.0 million people worldwide were currently known to have dementia. The report also stated that nearly 10.0 million new cases are reported every year.
  • Furthermore, the same source also stated that dementia is currently the seventh leading cause of death among all diseases and one of the major causes of disability and dependency among older people globally. Also, dementia is one of the major causes leading to frontotemporal disorders. Therefore, increasing cases of dementia are expected to surge the rate of frontotemporal disorders, thereby propelling market growth.
  • The increasing drug development grants and funding by the government, as well as non-government, are also boosting market growth. There are currently no FDA-approved disease-modifying treatments for frontotemporal disorders, and symptomatic treatment provides only limited benefit to patients.
  • Recent scientific findings have improved our knowledge of the underlying pathogenic mechanisms of a frontotemporal disorder, fostering the development of potential disease-modifying therapies. Therefore, to accelerate the research and drug development procedure, in December 2020, the Association for Frontotemporal Degeneration (AFTD) and the Alzheimer's Drug Discovery Foundation (ADDF) issued a joint request for proposals (RFP) for new research aimed at advancing and accelerating the diagnosis and treatment of frontotemporal disorders, the most common dementia in people under 60. The funding for this RFP is being provided through the Treat FTD Fund, with award recipients receiving up to USD 2.0 million. Thus, such a scenario is anticipated to accelerate the demand for frontotemporal disorders treatment over the forecast period.
  • However, cost issues and a lack of awareness across several regions will likely hinder market growth over the forecast period.

Frontotemporal Disorders Treatment Industry Segmentation

As per the scope of the report, frontotemporal disorders are forms of dementia caused by a family of brain diseases known as frontotemporal lobar degeneration (FTLD). It majorly involves a severe loss of thinking abilities that interferes with a person's ability to perform daily activities such as working, driving, and preparing meals. 

The frontotemporal disorders treatment market is segmented by drug class (cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others), disease indication (frontotemporal dementia, primary progressive aphasia, and movement disorders), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. 

The report offers the value (in USD million) for the above segments.

By Drug Class
Cognitive Enhancers
Antipsychotics
Antidepressants
CNS Stimulants
Other Drug Classes
By Disease Indication
Frontotemporal Dementia
Primary Progressive Aphasia
Movement Disorders
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Frontotemporal Disorders Treatment Market Size Summary

The frontotemporal disorders treatment market is poised for significant growth, driven by the increasing prevalence of dementia and related cognitive impairments. The COVID-19 pandemic has exacerbated these conditions, leading to a rise in cases and subsequently boosting market demand. The lack of FDA-approved disease-modifying treatments highlights the need for research and development, which is being supported by government and non-government funding initiatives. These efforts are aimed at advancing the understanding and treatment of frontotemporal disorders, particularly as they are becoming more common among younger populations. The market is characterized by a fragmented landscape with both major and minor players, all vying to capture market share through innovative treatments and strategic partnerships.

North America is expected to lead the market, fueled by a growing geriatric population and a high incidence of dementia and anxiety disorders. The region's dominance is further supported by extensive research activities and the presence of key market players. Recent product launches and regulatory approvals, such as those by the FDA, are anticipated to drive market expansion. The competitive environment is marked by collaborations and acquisitions among major companies, which are crucial for maintaining market position and fostering innovation. Despite the promising growth prospects, challenges such as cost issues and lack of awareness in certain regions may impede market progress.

Explore More

Frontotemporal Disorders Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Prevalence of Dementia and Other Frontotemporal Disorders

      2. 1.2.2 Increasing Drug Development Grants and Funding by Government as well as Non-Government Organisations

    3. 1.3 Market Restraints

      1. 1.3.1 Cost Issues and Lack of Awareness across Several Regions

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Drug Class

      1. 2.1.1 Cognitive Enhancers

      2. 2.1.2 Antipsychotics

      3. 2.1.3 Antidepressants

      4. 2.1.4 CNS Stimulants

      5. 2.1.5 Other Drug Classes

    2. 2.2 By Disease Indication

      1. 2.2.1 Frontotemporal Dementia

      2. 2.2.2 Primary Progressive Aphasia

      3. 2.2.3 Movement Disorders

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Online Pharmacies

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Frontotemporal Disorders Treatment Market Size FAQs

The Frontotemporal Disorders Treatment Market is projected to register a CAGR of 7.20% during the forecast period (2024-2029)

Johnson & Johnson , Apotex Inc. , Auro Pharma , Pfizer Inc. and Teva Pharmaceuticals USA, Inc. are the major companies operating in the Frontotemporal Disorders Treatment Market.

Frontotemporal Disorders Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)